Anadys Pharmaceuticals, Inc. has suspended dosing of ANA 975 in patients with hepatitis C virus infection in its ongoing phase Ib clinical trial

Source: Reactions, Volume 1, Number 1109, 2006-07-08 , pp. 3-3(1)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Keywords: ANA-975, adverse reactions; ANA-975, pharmacodynamics; Development-status; Hepatitis-C; Novartis; Research-and-development; Various-toxicities, drug-induced

Document Type: Short communication

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$27.95 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A